Alector announces achievement of target enrollment in the pivotal infront-3 phase 3 clinical trial of latozinemab in individuals with frontotemporal dementia due to a progranulin gene mutation (ftd-grn)

--101 symptomatic ftd-grn participants enrolled in infront-3 -- south san francisco, calif., oct. 27, 2023 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has achieved target enrollment in infront-3, the pivotal phase 3 clinical trial of latozinemab (al001). infront-3 is evaluating the safety and efficacy of latozinemab in slowing disease progression in individuals with frontotemporal dementia due to a progranulin gene mutation (ftd-grn). latozinemab is an investigational human monoclonal antibody designed to block sortilin, a degradation receptor for progranulin (pgrn). it is intended to elevate pgrn levels and enhance the activity of microglia, the primary cells of the brain's innate immune system. latozinemab is the most advanced pgrn modulating product candidate in clinical trials and the most advanced potential treatment for ftd-grn. latozinemab is being developed in collaboration with gsk.
ALEC Ratings Summary
ALEC Quant Ranking